drugset / Trial / NCT05188508
Pembrolizumab, Olaparib, and Temozolomide for People With Glioma
Phase 2
Recruiting
57 enrolled
Memorial Sloan Kettering Cancer Center
Merck Sharp & Dohme LLC · collab
Non-randomizedParallel-groupOpen-labelTreatment
Summary
This study will test the safety and effectiveness of a combination of pembrolizumab, olaparib, and temozolomide to see how well these drugs work when given together in people with a glioma that either did not respond to previous treatment or came back after treatment.
Timeline
- Start
- 2022-01-14
- Primary completion
- 2027-01
- Completion
- 2027-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Olaparib | Small molecule | 200 mg | Oral |
| Subject | Pembrolizumab | Monoclonal antibody | 200 mg | Intravenous |
| Subject | Temozolomide | Small molecule | 50 mg/m2 | Oral |